title: Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase.
authors.affiliation: Department of Hematology, Department of Cellular Biotechnologies and Hematology, La Sapienza University, Rome, Italy breccia@bce.uniroma1.it.
authors.forename: Massimo
authors.initials: M
authors.lastname: Breccia
authors.affiliation: Hematology, S.Eugenio Hospital, Rome, Italy.
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Abruzzese
authors.affiliation: IRCCS Cà Granda Policlinico, Milan, Italy.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Iurlo
authors.affiliation: Careggi Hospital, Florence, Italy.
authors.forename: Antonella
authors.initials: A
authors.lastname: Gozzini
authors.affiliation: Department of Hematology, Pesaro, Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Isidori
authors.affiliation: Department of Hematology, Frosinone, Italy.
authors.forename: Domenica
authors.initials: D
authors.lastname: Gangemi
authors.affiliation: S.Giovanni Battista Hospital, Turin, Italy.
authors.forename: Patrizia
authors.initials: P
authors.lastname: Pregno
authors.affiliation: Department of Hematology, Department of Cellular Biotechnologies and Hematology, La Sapienza University, Rome, Italy.
authors.forename: Giuliana
authors.initials: G
authors.lastname: Alimena
mesh_terms: D000328:Adult; D000368:Aged; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000401:mortality; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D011724:Pyridazines / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D007093:Imidazoles; D047428:Protein Kinase Inhibitors; D011724:Pyridazines; C545373:ponatinib
keywords: chronic myeloid leukemia; ponatinib; prognosis